Abpro celebrates business combination close; raises $10M and secures $50M equity facility

Abpro Holdings, Inc.

Business combination with ACAB closed Nov 13, 2024; Nasdaq bell ringing ceremony held Dec 12.
Raised $10M gross proceeds ($7M PIPE + $2.76M convertible note) and secured up to $50M equity facility from Yorkville.
Funds to support development of antibody pipeline for HER2+ cancers, wet AMD, DME, and infectious diseases.
Partnered with Celltrion to advance ABP 102 T-cell engager for HER2+ breast, gastric, pancreatic cancers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.